KRAS G12C clinical trials at University of California Health

4 in progress, 3 open to eligible people

Showing trials for

  • FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

    open to eligible people ages 18 years and up

    The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.

    at UC Irvine UCSD UCSF

  • BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18 years and up

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    at UC Davis UCSD UCSF

  • BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    open to eligible people ages 18 years and up

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.

    at UCLA UCSD UCSF

  • ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

    Sorry, in progress, not accepting new patients

    This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.

    at UC Irvine UCLA

Our lead scientists for KRAS G12C research studies include .

Last updated: